146 related articles for article (PubMed ID: 31022472)
1. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.
Choi S; Chu J; Kim B; Ha SY; Kim ST; Lee J; Kang WK; Han H; Sohn I; Kim KM
J Mol Diagn; 2019 Jul; 21(4):612-622. PubMed ID: 31022472
[TBL] [Abstract][Full Text] [Related]
2. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
3. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
5. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
7. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
8. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
9. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
[TBL] [Abstract][Full Text] [Related]
10. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
[TBL] [Abstract][Full Text] [Related]
11. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
[TBL] [Abstract][Full Text] [Related]
15. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
Yang SR; Bouhlal Y; De La Vega FM; Ballard M; Kuo CJ; Vilborg A; Jensen G; Allison K
Mod Pathol; 2020 Aug; 33(8):1546-1556. PubMed ID: 32161378
[TBL] [Abstract][Full Text] [Related]
19. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
20. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]